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The current update of the ACC/AHA/NASPE Guidelinesfor Implantation of Cardiac Pacemakers and Antiarrhyth-
mia Devices includes several significant changes in the
recommendations and in the supporting narrative portion. In
this summary, we list the updated recommendations along
with the respective 1998 recommendations, each one accom-
panied by a brief comment outlining the rationale for the
changes, additions, or deletions. All new or revised recom-
mendations are listed in the second column and appear in
boldface type. References that support either the 1998 rec-
ommendations that have not changed or the new or revised
recommendations are noted in parentheses at the end of each
recommendation. The reader is referred to the full-text
version of the guidelines posted on the American College of
Cardiology (ACC), American Heart Association (AHA), and
North American Society for Pacing and Electrophysiology
(NASPE) World Wide Web sites for a more detailed expo-
sition of the rationale for these changes. In addition to the
recommendation changes listed here, this update includes
an expanded section on the selection of pacemakers and
implantable cardioverter-defibrillators (ICDs) that reflects
the technical advances that have taken place since 1998. A
brief expanded summary of pacemaker follow-up proce-
dures is also new to these guidelines. For both of these
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expanded sections, the reader is referred to the online
full-text version.
In preparing this update, the committee was guided by the
following principles:
(1) Changes in recommendations and levels of evidence
were made either because of new randomized trials or
because of the accumulation of new clinical evidence
and the development of clinical consensus.
(2) The committee is cognizant of the healthcare, logistic,
and financial implications of recent trials and factored
in these considerations in arriving at the class level of
certain recommendations.
(3) Minor wording changes were made to render some
recommendations more precise.
(4) The committee wishes to re-emphasize that the recom-
mendations in the guideline apply to most patients but
may require modification by existing situations that only
the primary treating physician can evaluate properly.
(5) All of the listed recommendations for implantation of
a device presume the absence of inciting causes that
may be eliminated without detriment to the patient (eg,
nonessential drug therapy).
(6) The committee endeavored to maintain consistency
of recommendations in this and other previously
published guidelines. In the section on atrioventric-
ular (AV) block associated with acute myocardial
infarction (AMI), the recommendations follow
closely those in the ACC/AHA Guideline for the
Management of Patients With Acute Myocardial
Infarction (1). However, given the rapid evolution of
pacemaker/ICD science, it has not always been
possible to maintain consistency with other guide-
lines. An example of such a discrepancy can be
found in Section I-H, in which the recommendation
for biventricular pacing in selected patients with
heart failure has been listed under Class IIa, whereas in
the ACC/AHA Guideline for the Evaluation and Man-
agement of Chronic Heart Failure in the Adult (2),
biventricular pacing is cited as an investigational
procedure.
The ACC/AHA classifications I, II, and III are used to
summarize indications as follows:
Class I: Conditions for which there is evidence and/or
general agreement that a given procedure or
treatment is useful and effective.
Class II: Conditions for which there is conflicting evi-
dence and/or a divergence of opinion about the
usefulness/efficacy of a procedure or treatment.
IIa: Weight of evidence/opinion is in favor of
usefulness/efficacy.
IIb: Usefulness/efficacy is less well established
by evidence/opinion.
Class III: Conditions for which there is evidence and/or
general agreement that the procedure/treatment is
not useful/effective and in some cases may be
harmful.
The weight of the evidence was ranked highest (A) if the data
were derived from multiple randomized clinical trials that
involved large numbers of patients and intermediate (B) if the
data were derived from a limited number of randomized trials
that involved small numbers of patients or from careful
analyses of nonrandomized studies or observational regis-
tries. A lower rank (C) was given when expert consensus was
the primary basis for the recommendation.
1998 Recommendation
2002 New or Revised
Recommendations Comments
SECTION I-A: PACING FOR ACQUIRED ATRIOVENTRICULAR BLOCK IN ADULTS
Recommendations for Permanent Pacing in Acquired Atrioventricular Block in Adults
Class I Class I Class I
1. Third-degree AV block at any anatomic
level, associated with any one of the following
conditions:
a. Bradycardia with symptoms presumed to
be due to AV block. (Level of Evidence: C)
b. Arrhythmias and other medical conditions
that require drugs that result in symptomatic
bradycardia. (Level of Evidence: C)
c. Documented periods of asystole greater
than or equal to 3.0 seconds or any escape
rate less than 40 beats per minute (bpm) in
awake, symptom-free patients. (Level of
Evidence: B, C)
d. After catheter ablation of the AV junction.
(Level of Evidence: B, C) There are no trials to
assess outcome without pacing, and pacing is
virtually always planned in this situation unless
the operative procedure is AV junction
modification.
e. Postoperative AV block that is not
expected to resolve. (Level of Evidence: C)
1. Third-degree and advanced
second-degree AV block at any anatomic
level, associated with any one of the
following conditions:
a. Bradycardia with symptoms (including
heart failure) presumed to be due to AV
block. (Level of Evidence: C)
b. (No change)
c. Documented periods of asystole
greater than or equal to 3.0 seconds (3) or
any escape rate less than 40 beats per
minute (bpm) in awake, symptom-free
patients (4,5). (Levels of Evidence: B, C)
d. After catheter ablation of the AV
junction. (Levels of Evidence: B, C) There
are no trials to assess outcome without
pacing, and pacing is virtually always
planned in this situation unless the
operative procedure is AV junction
modification (6,7).
e. Postoperative AV block that is not
The changes emphasize the importance of
the site of the block and introduce “advanced
second-degree AV block” as a class I
indication. This recommendation is based on
several observational studies and is supported
by a wealth of clinical experience. The
narrative portion of this section also
emphasizes that the site of origin of the
escape rhythm in cases of advanced AV block
is as important (or more important) than the
escape rate itself.
In recommendation 1a, heart failure is
specifically introduced as a major symptom
that merits consideration when dealing with AV
block–induced bradycardia.
In recommendation 1e, “cardiac surgery”
was added to specifically define the situation(s)
in which this recommendation applies.
Recommendation 1f has been amplified to
indicate that pacing therapy is recommended
in patients with neuromuscular diseases and
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Recommendations Comments
f. Neuromuscular diseases with AV block
such as myotonic muscular dystrophy,
Kearns-Sayre syndrome, Erb’s dystrophy
(limb-girdle), and peroneal muscular atrophy.
(Level of Evidence: B)
expected to resolve after cardiac surgery.
(Level of Evidence: C) (8–10)
f. Neuromuscular diseases with AV block,
such as myotonic muscular dystrophy,
Kearns-Sayre syndrome, Erb’s dystrophy
(limb-girdle), and peroneal muscular
atrophy, with or without symptoms,
because there may be unpredictable
progression of AV conduction disease.
(Level of Evidence: B) (11–17)
third-degree AV block whether or not they are
symptomatic, in view of the unpredictable
progression of AV conduction in this group of
diseases.
2. Second-degree AV block regardless of
type or site of block, with associated
symptomatic bradycardia. (Level of Evidence:
B) (18)
No change
Class IIa Class IIa Class IIa
1. Asymptomatic third-degree AV block at
any anatomic site with average awake
ventricular rates of 40 bpm or faster. (Level of
Evidence: B, C)
1. Asymptomatic third-degree AV block at
any anatomic site with average awake
ventricular rates of 40 bpm or faster
especially if cardiomegaly or left ventricular
(LV) dysfunction is present. (Levels of
Evidence: B, C)
This change introduces the concept that
cardiomegaly and LV dysfunction are important
considerations in the decision-making process
to implant a pacemaker in asymptomatic
patients with third-degree AV block and
otherwise “acceptable” heart rates.
2. Asymptomatic type II second-degree AV
block. (Level of Evidence: B)
2. Asymptomatic type II second-degree
AV block with a narrow QRS. When type II
second-degree AV block occurs with a wide
QRS, pacing becomes a Class I
recommendation (see next section
regarding Pacing for Chronic Bifascicular
and Trifascicular Block). (Level of Evidence:
B) (19,20)
Based on reports and clinical experience,
the change in this recommendation calls
attention to the site of the block and
emphasizes that a wide QRS complex in
patients with type II second-degree AV block
suggests the presence of diffuse conduction
system disease and constitutes an indication
for pacing therapy even in asymptomatic
patients.
3. Asymptomatic type I second-degree AV
block at intra- or infra-His levels found
incidentally at electrophysiological study
performed for other indications. (Level of
Evidence: B)
3. Asymptomatic type I second-degree AV
block at intra- or infra-His levels found at
electrophysiological study performed for
other indications. (Level of Evidence: B)
(18–21)
Minor wording change deleting an
unnecessary word (incidentally)
4. First-degree AV block with symptoms
suggestive of pacemaker syndrome and
documented alleviation of symptoms with
temporary AV pacing. (Level of Evidence: B)
4. First- or second-degree AV block with
symptoms similar to those of pacemaker
syndrome. (Level of Evidence: B) (22,23)
Wording change to clarify that symptoms
resulting from first- or second-degree AV block
may be similar to those of the pacemaker
syndrome rather than suggestive of this
syndrome per se.
Class IIb Class IIb Class IIb
1. Marked first-degree AV block (more than
0.30 seconds) in patients with LV dysfunction
and symptoms of congestive heart failure in
whom a shorter AV interval results in
hemodynamic improvement, presumably by
decreasing left atrial filling pressure. (Level of
Evidence: C) (24)
No change
2. Neuromuscular diseases such as
myotonic muscular dystrophy, Kearns-Sayre
syndrome, Erb’s dystrophy (limb-girdle),
and peroneal muscular atrophy with any
degree of AV block (including first-degree
AV block) with or without symptoms,
because there may be unpredictable
progression of AV conduction disease.
(Level of Evidence: B) (11–17)
New recommendation for pacemaker
insertion in patients with neuromuscular
diseases and second- or first-degree AV block,
ie, lesser degrees of AV block than those listed
under Class I recommendation 1f.
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Class III Class III Class III
1. Asymptomatic first-degree AV block.
(Level of Evidence: B) (25)
(See also “Pacing for Chronic Bifascicular and
Trifascicular Block”)
No change
2. Asymptomatic type I second-degree AV
block at the supra-His (AV node) level or not
known to be intra- or infra-Hisian. (Level of
Evidence: B, C) (18)
No change
3. AV block expected to resolve and unlikely
to recur (26) (eg, drug toxicity, Lyme disease).
(Level of Evidence: B)
3. AV block expected to resolve and/or
unlikely to recur (26) (eg, drug toxicity,
Lyme disease, or during hypoxia in sleep
apnea syndrome in absence of symptoms)
(Level of Evidence: B)
Addition of hypoxia occurring during periods
of sleep apnea as a cause of transient AV
block that is unlikely to recur once sleep
apnea syndrome has been treated.
SECTION I-B: PACING FOR CHRONIC BIFASCICULAR AND TRIFASCICULAR BLOCK
Recommendations for Permanent Pacing in Chronic Bifascicular and Trifascicular Block
Class I Class I Class I
1. Intermittent third-degree AV block. (Level
of Evidence: B) (27–33)
No change
2. Type II second-degree AV block. (Level of
Evidence: B) (34–36)
No change
3. Alternating bundle-branch block. (Level
of Evidence: C) (37)
New Class I recommendation that adds
alternating bundle branch block to the
manifestations of fascicular block that indicate
pacing therapy. This recommendation was not
explicitly stated in the previous version.
Class IIa Class IIa Class IIa
1. Syncope not proved to be due to AV
block when other likely causes have been
excluded, specifically ventricular tachycardia
(VT). (Level of Evidence: B)
1. Syncope not demonstrated to be due to
AV block when other likely causes have been
excluded, specifically ventricular tachycardia
(VT). (Level of Evidence: B) (38–55)
Change of “proved” to “demonstrated”
because it may be very difficult to prove the
cause of syncope.
2. Incidental finding at electrophysiological
study of markedly prolonged HV interval (greater
than or equal to 100 milliseconds) in
asymptomatic patients. (Level of Evidence: B) (47)
No change
3. Incidental finding at electrophysiological
study of pacing-induced infra-His block that is
not physiological. (Level of Evidence: B) (54)
No change
Class IIb Class IIb Class IIb
1. Neuromuscular diseases such as
myotonic muscular dystrophy, Kearns-Sayre
syndrome, Erb’s dystrophy (limb-girdle),
and peroneal muscular atrophy with any
degree of fascicular block with or without
symptoms, because there may be
unpredictable progression of AV conduction
disease. (Level of Evidence: C) (11–17)
New Class IIb recommendation for pacing
therapy in patients with neuromuscular
diseases and fascicular block. Clinical
experience suggests that progression of AV
conduction disturbance is unpredictable, and
high-grade AV block can develop even in
asymptomatic patients with these diseases.
Class III Class III Class III
1. Fascicular block without AV block or
symptoms. (Level of Evidence: B) (41,43,46,47)
No change
2. Fascicular block with first-degree AV
block without symptoms. (Level of Evidence: B)
(41,43,46,47)
No change
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SECTION I-C: PACING FOR ATRIOVENTRICULAR BLOCK ASSOCIATED WITH ACUTE MYOCARDIAL INFARCTION
Recommendations for Permanent Pacing After the Acute Phase of Myocardial Infarction
Class I Class I Class I
1. Persistent second-degree AV block in the
His-Purkinje system with bilateral
bundle-branch block or third-degree AV block
within or below the His-Purkinje system after
AMI. (Level of Evidence: B) (36,56–60)
No change
2. Transient advanced (second- or
third-degree) infranodal AV block and
associated bundle-branch block. If the site of
block is uncertain, an electrophysiological
study may be necessary. (Level of Evidence: B)
(56,57)
No change
3. Persistent and symptomatic second- or
third-degree AV block. (Level of Evidence: C)
No change
Class IIb Class IIb Class IIb
1. Persistent second- or third-degree AV
block at the AV node level. (Level of Evidence:
B) (20)
No change
Class III Class III Class III
1. Transient AV block in the absence of
intraventricular conduction defects. (Level of
Evidence: B ) (56)
No change
2. Transient AV block in the presence of
isolated left anterior fascicular block. (Level of
Evidence: B) (58)
No change
3. Acquired left anterior fascicular block in
the absence of AV block. (Level of Evidence: B)
(56)
No change
4. Persistent first-degree AV block in the
presence of bundle-branch block that is old or
age indeterminate. (Level of Evidence: B) (56)
*These recommendations generally follow
the ACC/AHA Guidelines for the Management of
Patients With Acute Myocardial Infarction (61)
No change
SECTION I-D: PACING IN SINUS NODE DYSFUNCTION
Recommendations for Permanent Pacing in Sinus Node Dysfunction
Class I Class I Class I
1. Sinus node dysfunction with documented
symptomatic bradycardia, including frequent
sinus pauses that produce symptoms. In some
patients, bradycardia is iatrogenic and will
occur as a consequence of essential long-term
drug therapy of a type and dose for which
there are no acceptable alternatives. (Level of
Evidence: C) (5,62,63)
No change
2. Symptomatic chronotropic incompetence.
(Level of Evidence: C) (5,62–65)
No change
Class IIa Class IIa Class IIa
1. Sinus node dysfunction occurring
spontaneously or as a result of necessary drug
therapy, with heart rate less than 40 bpm
when a clear association between significant
symptoms consistent with bradycardia and the
actual presence of bradycardia has not been
documented. (Level of Evidence: C)
(4,5,62,63,66,67)
No change
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2. Syncope of unexplained origin when
major abnormalities of sinus node function
are discovered or provoked in
electrophysiological studies (Level of
Evidence: C) (68,69)
New Class IIa recommendation for pacing
therapy in patients with syncope, no other
demonstrable cause, and who were found to
have spontaneous or provocable sinus node
dysfunction at electrophysiological study.
Class IIb Class IIb Class IIb
1. In minimally symptomatic patients,
chronic heart rate less than 30 bpm while
awake. (Level of Evidence: C)
1. In minimally symptomatic patients,
chronic heart rate less than 40 bpm while
awake. (Level of Evidence: C)
(4,5,62,63,66,67)
The change of awake heart rate from 30 to
40 bpm was made on the basis of clinical
experience and provides the clinician more
flexibility to consider pacing in patients with
suspected sinus node dysfunction, in whom a
firm diagnosis cannot be made.
Class III Class III Class III
1. Sinus node dysfunction in asymptomatic
patients, including those in whom substantial
sinus bradycardia (heart rate less than 40
bpm) is a consequence of long-term drug
treatment.
No change
2. Sinus node dysfunction in patients with
symptoms suggestive of bradycardia that are
clearly documented as not associated with a
slow heart rate.
No change
3. Sinus node dysfunction with symptomatic
bradycardia due to nonessential drug therapy.
No change
SECTION I-E: PREVENTION AND TERMINATION OF TACHYARRHYTHMIAS BY PACING
Recommendations for Permanent Pacemakers That Automatically Detect and Pace to Terminate Tachycardias
Class I Class I Class I
1. Symptomatic recurrent supraventricular
tachycardia that is reproducibly terminated by
pacing after drugs and catheter ablation fail to
control the arrhythmia or produce intolerable
side effects. (Level of Evidence: C)
This recommendation was downgraded from
Class I to Class IIa. Committee consensus was
that it is highly unlikely that treatment with
drugs and/or ablation therapy would fail to
control supraventricular tachycardia (SVT) (see
below).
2. Symptomatic recurrent sustained VT as
part of an automatic defibrillator system. (Level
of Evidence: B)
Deleted because this indication is dealt with
in the ICD section.
Class IIa Class IIa Class IIa
1. Symptomatic recurrent SVT that is
reproducibly terminated by pacing in the
unlikely event that catheter ablation and/or
drugs fail to control the arrhythmia or
produce intolerable side effects. (Level of
Evidence: C) (70–74)
The rewording of this previously Class I
recommendation is intended to convey that
ablation and/or drugs are effective therapies
for SVT, and it is unlikely that pacing therapy
will be required.
Class IIb Class IIb Class IIb
1. Recurrent SVT or atrial flutter that is
reproducibly terminated by pacing as an
alternative to drug therapy or ablation. (Level
of Evidence: C) (70–75)
No change
Class III Class III Class III
1. Tachycardias frequently accelerated or
converted to fibrillation by pacing.
No change
2. The presence of accessory pathways with
the capacity for rapid anterograde conduction
whether or not the pathways participate in the
mechanism of the tachycardia.
No change
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SECTION I-E: PREVENTION AND TERMINATION OF TACHYARRHYTHMIAS BY PACING (continued)
Pacing Recommendations to Prevent Tachycardia
Class I Class I Class I
1. Sustained pause-dependent VT, with or
without prolonged QT, in which the efficacy of
pacing is thoroughly documented. (Level of
Evidence: C) (76,77)
No change
Class IIa Class IIa Class IIa
1. High-risk patients with congenital long-QT
syndrome. (Level of Evidence: C) (76,77)
No change
Class IIb Class IIb Class IIb
1. AV re-entrant or AV node re-entrant
supraventricular tachycardia not responsive to
medical or ablative therapy. (Level of Evidence:
C) (71,72,78)
No change
2. Prevention of symptomatic, drug
refractory, recurrent atrial fibrillation. (Level of
Evidence: C)
2. Prevention of symptomatic,
drug-refractory, recurrent atrial fibrillation
in patients with coexisting sinus node
dysfunction. (Level of Evidence: B) (79–81)
This recommendation was revised and the
level of evidence upgraded to “B” to reflect the
available information. Several studies suggest
that in some patients with recurrent atrial
fibrillation and coexisting sinus node
dysfunction, atrial-based pacing reduces the
recurrence rate of this arrhythmia.
Class III Class III Class III
1. Frequent or complex ventricular ectopic
activity without sustained VT in the absence of
the long-QT syndrome.
No change
2. Long-QT syndrome due to reversible
causes.
2. Torsade de Pointes VT due to
reversible causes.
Wording change because the arrhythmia is
the Torsade de Pointes VT and not the long-QT
syndrome.
SECTION I-F: PACING IN HYPERSENSITIVE CAROTID SINUS AND NEUROCARDIOGENIC SYNCOPE
Recommendations for Permanent Pacing in Hypersensitive Carotid Sinus Syndrome and Neurocardiogenic Syncope
Class I Class I Class I
1. Recurrent syncope caused by carotid
sinus stimulation; minimal carotid sinus
pressure induces ventricular asystole of more
than 3-second duration in the absence of any
medication that depresses the sinus node or
AV conduction. (Level of Evidence: C) (82,83)
No change
Class IIa Class IIa Class IIa
1. Recurrent syncope without clear,
provocative events and with a hypersensitive
cardioinhibitory response. (Level of Evidence:
C) (82,83)
No change
2. Syncope of unexplained origin when
major abnormalities of sinus node function or
AV conduction are discovered or provoked in
electrophysiological studies. (Level of Evidence:
C)
Deleted from this section and more
appropriately placed in the Sinus Node
Dysfunction section as Recommendation #2,
Class IIa.
3. Significantly symptomatic and
recurrent neurocardiogenic syncope
associated with bradycardia documented
spontaneously or at the time of tilt-table
testing. (Level of Evidence: B) (84–87)
This recommendation was added to reflect
the results of trials that have demonstrated
that pacing therapy is effective in cases of
vasovagal syncope associated with episodes of
spontaneous or provoked bradycardia. The
level of evidence was set to “B” to reflect
published trials.
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Class IIb Class IIb Class IIb
1. Neurally mediated syncope with
significant bradycardia reproduced by a
head-up tilt with or without isoproterenol or
other provocative maneuvers. (Level of
Evidence: B)
Deleted
Class III Class III Class III
1. A hyperactive cardioinhibitory response to
carotid sinus stimulation in the absence of
symptoms.
1. A hyperactive cardioinhibitory response
to carotid sinus stimulation in the absence
of symptoms or in the presence of vague
symptoms such as dizziness,
lightheadedness, or both.
(Level of Evidence: C)
This Class III recommendation replaces the
prior recommendations #1 and #2 for the sake
of simplicity.
2. A hyperactive cardioinhibitory response to
carotid sinus stimulation in the presence of
vague symptoms such as dizziness,
lightheadedness, or both.
Deleted
3. Recurrent syncope, lightheadedness, or
dizziness in the absence of a hyperactive
cardioinhibitory response. (Level of Evidence:
C)
This becomes #2.
4. Situational vasovagal syncope in which
avoidance behavior is effective. (Level of
Evidence: C)
This becomes #3.
SECTION I-G: PACING IN CHILDREN, ADOLESCENTS, AND PATIENTS WITH CONGENITAL HEART DISEASE
Recommendations for Permanent Pacing in Children, Adolescents, and Patients With Congenital Heart Disease
Class I Class I Class I
1. Advanced second- or third-degree AV
block associated with symptomatic
bradycardia, congestive heart failure, or low
cardiac output. (Level of Evidence: C)
1. Advanced second- or third-degree AV
block associated with symptomatic
bradycardia, ventricular dysfunction, or low
cardiac output. (Level of Evidence: C)
This recommendation was reworded,
substituting “ventricular dysfunction” for
“congestive heart failure” to reflect
accumulating clinical experience that
ventricular dysfunction adversely affects the
prognosis of patients with congenital
third-degree AV block even in the absence of
overt heart failure.
2. Sinus node dysfunction with correlation of
symptoms during age-inappropriate
bradycardia. The definition of bradycardia
varies with the patient’s age and expected
heart rate. (Level of Evidence: B) (3,5,88)
No change
3. Postoperative advanced second- or
third-degree AV block that is not expected to
resolve after cardiac surgery. (Level of
Evidence: B, C)
3. Postoperative advanced second- or
third-degree AV block that is not expected
to resolve or persists at least 7 days after
cardiac surgery. (Level of Evidence: B, C
(89,90)
Reworded recommendation to specify that
AV block that persists for more than 7 days
after cardiac surgery is unlikely to resolve and
is best treated with the implantation of a
pacemaker. The change was made because of
accumulating clinical experience and published
studies demonstrating adverse prognosis in
such patients who did not receive a permanent
pacemaker for rate support.
4. Congenital third-degree AV block with a
wide QRS escape rhythm or ventricular
dysfunction. (Level of Evidence: B)
4. Congenital third-degree AV block with
a wide QRS escape rhythm, complex
ventricular ectopy, or ventricular
dysfunction. (Level of Evidence: B) (91–93)
“Complex ventricular ectopy” was added to
the other elements of this recommendation to
reflect growing experience that in this setting,
prognosis is adversely affected by such ectopy
in the absence of rate support by a permanent
pacemaker.
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5. Congenital third-degree AV block in the
infant with a ventricular rate less than 50 to
55 bpm or with congenital heart disease and a
ventricular rate less than 70 bpm. (Level of
Evidence: B, C) (92,94)
No change
6. Sustained pause-dependent VT, with or
without prolonged QT, in which the efficacy of
pacing is thoroughly documented. (Level of
Evidence: B) (76,77,95,96)
No change
Class IIa Class IIa Class IIa
1. Bradycardia-tachycardia syndrome with
the need for long-term antiarrhythmic
treatment other than digitalis. (Level of
Evidence: C) (97,98)
No change
2. Congenital third-degree AV block beyond
the first year of life with an average heart rate
less than 50 bpm or abrupt pauses in
ventricular rate that are two or three times the
basic cycle length. (Level of Evidence: B)
2. Congenital third-degree AV block
beyond the first year of life with an average
heart rate less than 50 bpm, abrupt pauses
in ventricular rate that are two or three
times the basic cycle length, or associated
with symptoms due to chronotropic
incompetence. (Level of Evidence: B) (99)
Rewording of this recommendation to
include symptoms due to chronotropic
incompetence and abrupt pauses in ventricular
rate in young patients with third-degree AV
block after the first year of life. These events
have been found to affect prognosis in patients
with asymptomatic congenital third-degree AV
block.
3. Long-QT syndrome with 2:1 AV or
third-degree AV block. (Level of Evidence: B)
(100,101)
No change
4. Asymptomatic sinus bradycardia in the
child with complex congenital heart disease
with resting heart rate less than 35 bpm or
pauses in ventricular rate more than 3
seconds. (Level of Evidence: C)
4. Asymptomatic sinus bradycardia in the
child with complex congenital heart disease
with resting heart rate less than 40 bpm or
pauses in ventricular rate more than 3
seconds. (Level of Evidence: C)
The resting heart rate was changed from 35
to 40 bpm on the basis of clinical experience
and expert consensus.
5. Patients with congenital heart disease
and impaired hemodynamics due to sinus
bradycardia or loss of AV synchrony. (Level
of Evidence: C)
New recommendation for pacing in children
with impaired hemodynamics as a result of
sinus bradycardia or loss of AV synchrony.
Clinical experience has accumulated that
indicates that children with congenital heart
disease and hemodynamic impairment as a
result of these conditions have unfavorable
prognosis if not paced.
Class IIb Class IIb Class IIb
1. Transient postoperative third-degree AV
block that reverts to sinus rhythm with residual
bifascicular block. (Level of Evidence: C) (102)
No change
2. Congenital third-degree AV block in the
asymptomatic neonate, child, or adolescent
with an acceptable rate, narrow QRS complex,
and normal ventricular function. (Level of
Evidence: B)
2. Congenital third-degree AV block in
the asymptomatic infant, child, adolescent,
or young adult with an acceptable rate,
narrow QRS complex, and normal
ventricular function. (Level of Evidence: B)
(91,103)
Modification of this recommendation to
include “young adults” with congenital
third-degree AV block by clinical consensus.
3. Asymptomatic sinus bradycardia in the
adolescent with congenital heart disease with
resting heart rate less than 35 bpm or pauses
in ventricular rate more than 3 seconds. (Level
of Evidence: C)
3. Asymptomatic sinus bradycardia in the
adolescent with congenital heart disease
with resting heart rate less than 40 bpm or
pauses in ventricular rate more than 3
seconds. (Level of Evidence: C)
Change of resting heart rate from 35 to 40
bpm as a result of clinical experience and
expert consensus.
4. Neuromuscular diseases with any
degree of AV block (including first-degree
AV block), with or without symptoms,
because there may be unpredictable
progression of AV conduction disease.
New Class IIb recommendation for pacing in
children and adolescents with a neuromuscular
disease and any degree of AV block. This is
similar to the recommendation for pacing in
this situation for adults (Section I-A).
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Class III Class III Class III
1. Transient postoperative AV block with
return of normal AV conduction within 7 days.
(Level of Evidence: B)
1. Transient postoperative AV block with
return of normal AV conduction. (Level of
Evidence: B) (90,102)
Rewording of this Class III recommendation
to eliminate the 7-day window. There is
clinical evidence that patients with
postoperative AV block who regain normal AV
conduction at any time have generally
favorable prognosis without pacing.
2. Asymptomatic postoperative bifascicular
block with or without first-degree AV block.
(Level of Evidence: C)
No change
3. Asymptomatic type I second-degree AV
block. (Level of Evidence: C)
No change
4. Asymptomatic sinus bradycardia in the
adolescent with longest RR interval less than 3
seconds and minimum heart rate more than 40
bpm. (Level of Evidence: C) (104)
No change
SECTION I-H: PACING IN SPECIFIC CONDITIONS
1. HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY
Pacing Recommendations for Hypertrophic Cardiomyopathy
Class I Class I Class I
1. Class I indications for sinus node
dysfunction or AV block as previously
described. (Level of Evidence: C)
No change
Class IIb Class IIb Class IIb
1. Medically refractory, symptomatic
hypertrophic cardiomyopathy with significant
resting or provoked LV outflow obstruction.
(Level of Evidence: C)
1. Medically refractory, symptomatic
hypertrophic cardiomyopathy with
significant resting or provoked LV outflow
obstruction. (Level of Evidence: A)
(105–110)
No change in recommendation class. Level
of evidence raised from “C” to “A” on the
basis of published trials.
Class III Class III Class III
1. Patients who are asymptomatic or
medically controlled.
No change
2. Symptomatic patients without evidence of
LV outflow obstruction.
No change
2. IDIOPATHIC DILATED CARDIOMYOPATHY
Pacing Recommendations for Dilated Cardiomyopathy
Class I Class I Class I
1. Class I indications for sinus node
dysfunction or AV block as previously
described. (Level of Evidence: C)
No change
Class IIa Class IIa Class IIa
1. Biventricular pacing in medically
refractory, symptomatic New York Heart
Association (NYHA) class III or IV patients
with idiopathic dilated or ischemic
cardiomyopathy, prolonged QRS interval
(greater than or equal to 130 ms), LV
end-diastolic diameter greater than or equal
to 55 mm and ejection fraction less than or
equal to 35%. (Level of Evidence: A)
(111,112)
New recommendation for biventricular
pacing in patients with advanced heart failure,
specific indices of LV dysfunction, and
prolonged QRS duration. Multiple trials have
demonstrated clinical and structural cardiac
improvement with this form of therapy.
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Class IIb Class IIb Class IIb
1. Symptomatic, drug refractory dilated
cardiomyopathy with prolonged PR interval
when acute hemodynamic studies have
demonstrated hemodynamic benefit of pacing.
(Level of Evidence: C)
Deleted
Class III Class III Class III
1. Asymptomatic dilated cardiomyopathy. No change
2. Symptomatic dilated cardiomyopathy
when patients are rendered asymptomatic by
drug therapy.
No change
3. Symptomatic ischemic cardiomyopathy. 3. Symptomatic ischemic cardiomyopathy
when the ischemia is amenable to
intervention.
Modification of this recommendation to
clarify that pacing therapy is not indicated in
symptomatic ischemic cardiomyopathy when
the patient can be treated with
revascularization therapy.
SECTION I-H: PACING IN SPECIFIC CONDITIONS (continued)
3. CARDIAC TRANSPLANTATION
Pacing Recommendations After Cardiac Transplantation
Class I Class I Class I
1. Symptomatic bradyarrhythmias/
chronotropic incompetence not expected to
resolve and other Class I indications for
permanent pacing. (Level of Evidence: C)
No change
Class IIb Class IIb Class IIb
1. Symptomatic bradyarrhythmias/
chronotropic incompetence that, although
transient, may persist for months and require
intervention. (Level of Evidence: C)
No change
Class III Class III Class III
1. Asymptomatic bradyarrhythmias after
cardiac transplantation.
No change
SECTION II: INDICATIONS FOR IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR THERAPY
Recommendations for ICD Therapy
Class I Class I Class I
1. Cardiac arrest due to ventricular
fibrillation (VF) or VT not due to a transient or
reversible cause. (Level of Evidence: A)
(113–134)
No change
2. Spontaneous sustained VT. (Level of
Evidence: B)
2. Spontaneous sustained VT in
association with structural heart disease.
(Level of Evidence: B) (113–127)
This recommendation for ICD implantation
was modified with the addition of the
requirement for structural heart disease to be
present. This change was made because ICD
therapy is most efficacious in patients with
impaired LV performance. Conversely, VT
arising in structurally normal hearts can usually
be treated pharmacologically or with catheter
ablation.
3. Syncope of undetermined origin with
clinically relevant, hemodynamically significant
sustained VT or VF induced at
electrophysiological study when drug therapy is
ineffective, not tolerated, or not preferred.
(Level of Evidence: B) (127,133,135–140)
No change
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4. Nonsustained VT with coronary disease,
prior MI, LV dysfunction, and inducible VF or
sustained VT at electrophysiological study that
is not suppressible by a Class I antiarrhythmic
drug. (Level of Evidence: B)
4. Nonsustained VT in patients with
coronary disease, prior myocardial
infarction (MI), LV dysfunction, and
inducible VF or sustained VT at
electrophysiological study that is not
suppressible by a Class I antiarrhythmic
drug. (Level of Evidence: A) (141–143)
No substantive change. Level of evidence
raised from “B” to “A” as a result of newly
published studies.
5. Spontaneous sustained VT in patients
who do not have structural heart disease
that is not amenable to other treatments.
(Level of Evidence: C)
New recommendation for ICD implantation in
patients with sustained VT and structurally
normal hearts when alternative treatments
have failed (See #2 above)
Class IIa Class IIa Class IIa
Patients with LV ejection fraction of less
than or equal to 30%, at least one month
post myocardial infarction and three
months post coronary artery
revascularization surgery. (Level of
Evidence: B) (159)
New recommendation for implantation of an
ICD prophylactically in the defined population.
This recommendation is promulgated as a
result of a randomized trial that demonstrated
a 5.6% absolute risk reduction and a 31%
relative risk reduction for death in the patient
group receiving an ICD. The committee
consensus was that further risk stratification of
the referenced population might better define
the benefit of an ICD in such patients. The
reader should review the discussion regarding
this recommendation in the full-text guideline
on the ACC, AHA, and NASPE web sites.
Class IIb Class IIb Class IIb
1. Cardiac arrest presumed to be due to VF
when electrophysiological testing is precluded
by other medical conditions. (Level of
Evidence: C) (124,131,144,145)
No change
2. Severe symptoms attributable to
sustained ventricular tachyarrhythmias while
awaiting cardiac transplantation. (Level of
Evidence: C)
2. Severe symptoms (eg, syncope)
attributable to ventricular tachyarrhythmias
in patients awaiting cardiac transplantation.
(Level of Evidence: C) (146,147)
No substantive change. Syncope was added
as an example of “severe symptoms.”
3. Familial or inherited conditions with a
high risk for life-threatening ventricular
tachyarrhythmias such as long-QT syndrome or
hypertrophic cardiomyopathy. (Level of
Evidence: B) (27,39,148–154)
No change
4. Nonsustained VT with coronary artery
disease, prior MI, LV dysfunction, and inducible
sustained VT or VF at electrophysiological
study. (Level of Evidence: B)
(113,118,126,141,142,155,156)
No change
5. Recurrent syncope of undetermined
etiology in the presence of ventricular
dysfunction and inducible ventricular
arrhythmias at electrophysiological study when
other causes of syncope have been excluded.
(Level of Evidence: C)
No change
6. Syncope of unexplained etiology or
family history of unexplained sudden
cardiac death in association with typical or
atypical right bundle-branch block and
ST-segment elevations (Brugada syndrome).
(Level of Evidence: C) (157,158)
New recommendation for ICD implantation in
patients with the Brugada syndrome and
syncope or family history of sudden cardiac
death. Several reports suggest that ICD therapy
in patients with this syndrome is effective in
preventing sudden death.
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7. Syncope in patients with advanced
structural heart disease in which thorough
invasive and noninvasive investigation has
failed to define a cause. (Level of Evidence: C)
New recommendation based on clinical
experience and expert consensus. Patients with
advanced structural heart disease and syncope
of undetermined etiology despite thorough
investigation are likely to have an arrhythmic
cause of the syncope and thus may benefit
from ICD insertion.
Class III Class III Class III
1. Syncope of undetermined cause in a
patient without inducible ventricular
tachyarrhythmias. (Level of Evidence: C)
1. Syncope of undetermined cause in a
patient without inducible ventricular
tachyarrhythmias and without structural
heart disease. (Level of Evidence: C)
Modification of this recommendation to
exclude patients with structural heart disease
who fall under #7, Class IIb, above.
2. Incessant VT or VF. (Level of Evidence: C) No change
3. VF or VT resulting from arrhythmias
amenable to surgical or catheter ablation; for
example, atrial arrhythmias associated with the
Wolff-Parkinson-White syndrome, right
ventricular outflow tract VT, idiopathic left
ventricular tachycardia, or fascicular VT. (Level
of Evidence: C) (130,160–163)
No change
4. Ventricular tachyarrhythmias due to a
transient or reversible disorder (eg, AMI,
electrolyte imbalance, drugs, trauma). (Level of
Evidence: C) (164)
4. Ventricular tachyarrhythmias due to a
transient or reversible disorder (eg, AMI,
electrolyte imbalance, drugs, or trauma)
when correction of the disorder is
considered feasible and likely to
substantially reduce the risk of recurrent
arrhythmia. (Level of Evidence: B) (165–167)
Changed to address the issue of many
patients with structural heart disease who
experience cardiac arrest in the setting of
abnormal electrolytes. Such patients may still
be at risk for recurrent arrhythmic events and
may still benefit from ICD therapy.
5. Significant psychiatric illnesses that may
be aggravated by device implantation or may
preclude systematic follow-up. (Level of
Evidence: C) (168,169)
No change
6. Terminal illnesses with projected life
expectancy less than six months. (Level of
Evidence: C)
No change
7. Patients with coronary artery disease with
LV dysfunction and prolonged QRS duration in
the absence of spontaneous or inducible
sustained or nonsustained VT who are
undergoing coronary bypass surgery. (Level of
Evidence: B) (170)
No change
8. NYHA Class IV drug-refractory congestive
heart failure in patients who are not candidates
for cardiac transplantation. (Level of Evidence: C)
No change
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